Antihypertensive drug prescribing and persistence among new elderly users: Implications for persistence improvement interventions

Canadian Journal of Cardiology

Volumn 30, Issue 6, 2014, Pages 647-652

  Tu, Karen ^a,b,c   Anderson, Laura N ^a   Butt, Debra ^g   Quan, Hude ^d   Hemmelgarn, Brenda ^g   Campbell, Norm ^g   McAlister, Finlay ^g   Baclic, Oliver ^g   Bartlett, Gillian ^g   Chen, Guanmin ^g   Dai, Sulan ^g   Hill, Michael ^g   Johansen, Helen ^g   Khan, Nadia ^g   Lix, Lisa ^g   Onysko, Jay ^g   Smith, Mark ^g   Svenson, Larry ^g   Teare, Gary ^g   Walker, Robin ^g   Wielgosz, Andy ^g   more..

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL AFFECTING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CANADA; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INCOME; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRESCRIPTION; RURAL AREA; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS; DIURETICS; HEART FAILURE; HUMANS; HYPERTENSION; INCOME; LOGISTIC MODELS; MEDICATION ADHERENCE; MYOCARDIAL INFARCTION; ONTARIO; RETROSPECTIVE STUDIES; RURAL POPULATION; SODIUM CHLORIDE SYMPORTER INHIBITORS; STROKE; URBAN POPULATION;

EID: 84901448585     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.03.017     Document Type: Article

References (37)

1. Global Health Risks Mortality and Burden of Disease Attributable to Major Risks 2009, World Health Organization, Geneva, Switzerland.
2. Cushman W.C. The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression. J Clin Hypertens (Greenwich) 2003, 5(3 suppl 2):14-22.
3. Campbell N.R., Brant R., Johansen H., et al. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension 2009, 53:128-134.
4. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.
5. Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326:1427.
6. Perreault S., Dragomir A., White M., Lalonde L., Blais L., Bérard A. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med Aug 2009, 266(2):207-218.
7. Perreault S., Dragomir A., Roy L., et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol 2010, 69:74-84.
8. Kettani F.Z., Dragomir A., CÔté R., et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009, 40:213-220.
9. Chowdhury R., Khan H., Heydon E., et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J Aug 2013, 34:2940-2948.
10. Mccombs J., Nichol M., Newman C., Sclar D. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994, 32:214-226.
11. Sokol M., McGuigan K., Verbrugge R., Epstein R. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005, 43:521-530.
12. Rizzo J., Simons W. Varitations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997, 19:1446-1457.
13. Caro J., Speckman J. Existing treatment strategies: does noncompliance make a difference?. J Hypertens Suppl 1998, 16:S31-S34.
14. Lopert R., Shoemaker J.S., Davidoff A., et al. Medication adherence and Medicare expenditure among beneficiaries with heart failure. Am J Manag Care 2012, 18:556-563.
15. Kronish I.M., Woodward M., Sergie Z., et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation 2011, 123:1611-1621.
16. Naderi S.H., Bestwick J.P., Wald D.S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012, 125:882-887.e881.
17. Gee M.E., Campbell N.R., Gwadry-Sridhar F., et al. Antihypertensive medication use, adherence, stops, and starts in Canadians with hypertension. Can J Cardiol 2012, 28:383-389.
18. Iron K., Zagorski B.M., Sykora K., Manuel D.G. Living and dying in Ontario: an opportunity for improved health information. Institute for Clinical Evaluative Sciences (ICES) investigative report 2008, Canada, Toronto, Ontario.
19. Wilkins R. Automated geographic coding based on the Statistics Canada postal code conversion files, including postal codes through March 2009. Ottawa, Ontario, Canada: Statistics Canada; 2009.
20. Kokotailo R.A., Hill M.D. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke 2005, 36:1776-1781.
21. Quach S., Blais C., Quan H. Administrative data have high variation in validity for recording heart failure. Can J Cardiol 2010, 26:306-312.
22. Quan H., Li B., Saunders L.D., et al. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res 2008, 43:1424-1441.
23. Hux J.E., Ivis F., Flintoft V., Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002, 25:512-516.
24. The John Hopkins University Bloomberg School of Public Health HSRDC The John Hopkins Adjusted Clinical Groups® (ACG) Case-Mix System, version 6.0 release notes April 2003, The Johns Hopkins University, Baltimore, MD.
25. Gomes T, Juurlink D, Mamdani M. Comparative adherence to oxybutynin or tolterodine among older patients. Eur J Clinical Pharmacol 2012;68:1121.
26. Juurlink D.N., Gomes T., Lipscombe L.L., et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009, 339:b2942.
27. Gu Q., Burt V.L., Dillon C.F., Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation 2012, 126:2105-2114.
28. Lachaine J., Petrella R.J., Merikle E., Ali F. Choices, persistence and adherence to antihypertensive agents: evidence from RAMQ data. Can J Cardiol 2008, 24:269-273.
29. Selmer R., Blix H.S., Landmark K., Reikvam A. Choice of initial antihypertensive drugs and persistence of drug use-a 4-year follow-up of 78,453 incident users. Eur J Clin Pharmacol 2012, 68:1435-1442.
30. Yeaw J., Benner J.S., Walt J.G., Sian S., Smith D.B. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009, 15:728-740.
31. Patel B., Remigio-Baker R., Mehta D., et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens 2007, 9:692-700.
32. Bourgault C., Senecal M., Brisson M., Marentette M., Gregoire J.-P. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005, 19:607-613.
33. Saleh S.S., Szebenyi S., Carter J.A., Zacher C., Belletti D. Patterns and associated health services costs of antihypertensive drug modifications. J Clin Hypertens (Greenwich) 2008, 10:43-50.
34. Fitz-Simon N., Bennett K., Feely J. A review of studies of adherence with antihypertensive drugs using prescription databases. Ther Clin Risk Manag 2005, 1:93-106.
35. Friedman O., McAlister F.A., Yun L., Campbell N.R., Tu K. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in Ontario. Am J Med 2010, 123:173-181.
36. Qvarnström M., Kahan T., Kieler H., et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol 2013, 69:1955-1964.
37. Bautista L.E. Predictors of persistence with antihypertensive therapy: results from the NHANES. Am J Hypertens 2008, 21:183-188.